interChange Provider Important Message

Attention: Medical Providers and Pharmacies

Janssen COVID-19 Vaccine

The Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for emergency use of the Janssen COVID-19 Vaccine for the prevention of Coronavirus Disease 2019 (COVID-19) for individuals 18 years of age and older, as described in the Scope of Authorization (Section II), pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the FD&C Act or the Act) (21 U.S.C. 360bbb-3).

The addition of the single dose Janssen COVID-19 Vaccine expands the number of authorized COVID-19 vaccines to three (3).

As a reminder, claims submitted for the administration of a COVID-19 vaccine must include both the procedure code for the administration and the procedure code for the vaccine product administered (including the 11-digit National Drug Code (NDC)); otherwise, the detail for the administration will deny.

The Department of Social Services (DSS) is in the process of updating the Medicaid Management Information System (MMIS) system to allow the processing of the Janssen Covid-19 Vaccine administration claims and will provide a separate notification when the system is ready to accept these claims.

The pharmacy Point-of-Sale (POS) system is not impacted by the above-mentioned updates and is ready to accept claims for the Janssen COVID-19 Vaccine when submitted with the 11-digit Outer Package NDC of 59676-0580-15.

Vaccine Code	Vaccine Code Descriptor	Vaccine Administration Code(s)	Vaccine Manufacturer	Vaccine Name(s)	NDC 11 Labeler Product ID (Vial)	Dosing Interval
91303	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, $5x10^{10}$ viral particles/0.5mL dosage, for intramuscular use	0031A (Single dose)	Janssen	Janssen COVID-19 Vaccine	59676-0580-15 (Outer Package)	Not applicable

For information pertaining to the reimbursement for administering COVID-19 vaccines, providers are asked to refer to previously published guidance in PB 2021-05 and PB 2021-06.

gainwell